Wu Ke, Kwon Soon Hwan, Zhou Xuhan, Fuller Claire, Wang Xianyi, Vadgama Jaydutt, Wu Yong
Division of Cancer Research and Training, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90095, USA.
David Geffen School of Medicine at University of California, Los Angeles, CA 90095, USA.
Int J Mol Sci. 2024 Dec 6;25(23):13121. doi: 10.3390/ijms252313121.
The bioavailability of small-molecule drugs remains a critical challenge in pharmaceutical development, significantly impacting therapeutic efficacy and commercial viability. This review synthesizes recent advances in understanding and overcoming bioavailability limitations, focusing on key physicochemical and biological factors influencing drug absorption and distribution. We examine cutting-edge strategies for enhancing bioavailability, including innovative formulation approaches, rational structural modifications, and the application of artificial intelligence in drug design. The integration of nanotechnology, 3D printing, and stimuli-responsive delivery systems are highlighted as promising avenues for improving drug delivery. We discuss the importance of a holistic, multidisciplinary approach to bioavailability optimization, emphasizing early-stage consideration of ADME properties and the need for patient-centric design. This review also explores emerging technologies such as CRISPR-Cas9-mediated personalization and microbiome modulation for tailored bioavailability enhancement. Finally, we outline future research directions, including advanced predictive modeling, overcoming biological barriers, and addressing the challenges of emerging therapeutic modalities. By elucidating the complex interplay of factors affecting bioavailability, this review aims to guide future efforts in developing more effective and accessible small-molecule therapeutics.
小分子药物的生物利用度仍然是药物研发中的一个关键挑战,对治疗效果和商业可行性有重大影响。本综述综合了在理解和克服生物利用度限制方面的最新进展,重点关注影响药物吸收和分布的关键物理化学和生物学因素。我们研究了提高生物利用度的前沿策略,包括创新的制剂方法、合理的结构修饰以及人工智能在药物设计中的应用。纳米技术、3D打印和刺激响应递送系统的整合被视为改善药物递送的有前景的途径。我们讨论了采用整体、多学科方法优化生物利用度的重要性,强调早期考虑药物代谢动力学性质以及以患者为中心设计的必要性。本综述还探讨了如CRISPR-Cas9介导的个性化和微生物组调节等新兴技术,以实现定制化的生物利用度提高。最后,我们概述了未来的研究方向,包括先进的预测建模、克服生物屏障以及应对新兴治疗方式的挑战。通过阐明影响生物利用度的各种因素之间的复杂相互作用,本综述旨在指导未来开发更有效且更易获取的小分子治疗药物的工作。